The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo. Read More
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main causes of both community-acquired and hospital-acquired infections and has become resistant to almost all known available antibiotics. Researchers from Hong Kong Polytechnic University and collaborators reported on a new series of indole-benzosulfonamide oleanolic acid derivatives with the potential to be used against multidrug-resistant bacteria. Read More
Cycloicaritin (CICT) is a bioactive natural flavonoid extracted from Epimedium species with anti-inflammatory, antimicrobial or antiproliferative effects but with low bioavailability. Read More
Immpact Bio USA Inc. has obtained IND clearance from the FDA for IMPT-514, a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple sclerosis (MS). A phase I trial will focus on patients who have suboptimal disease control despite prior treatment with high efficacy disease-modifying therapies in all forms of MS. Read More
Zymedi Co. Ltd. has disclosed lysyl-tRNA synthetase (KARS)/laminin receptor (LR) interaction inhibitors reported to be useful for the treatment of cancer metastasis, autoimmune disease, inflammatory disorders, fibrosis and cardiovascular disorders. Read More
Novel antimalarials are urgently needed to face the challenge of increasing parasite resistance. The isoprenoid precursor biosynthesis pathway is an attractive target for developing novel antimalarial drugs, being an essential and specific pathway in apicomplexan parasites. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Monopar Therapeutics Inc. has received Human Research Ethics Committee (HREC) clearance in Australia to initiate a phase I therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101, which is highly selective against the urokinase plasminogen activator receptor (uPAR). Read More
Researchers at Centre Hospitalier Universitaire de Grenoble Alpes, Centre National de la Recherche Scientifique, Commissariat à l’Energie Atomique, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes and Université Libre de Bruxelles have synthesized calix[4]arene compounds reported to be useful for treatment of cancer, metastatic cancer, and bacterial, viral, fungal and parasitic infections. Read More
Shanghai Kygent Pharmaceutical Co. Ltd. has identified DNA methyltransferase 1 (DNMT1) inhibitors reported to be useful for the treatment of cancer. Read More
G protein-coupled receptor kinase 2 (GRK2) is a crucial kinase that has been shown to interact with multiple signaling molecules under different pathological conditions, including fibrosis. Read More
Oxford University Innovations Ltd. has divulged Egl nine homolog 1 (EGLN1; HPH-2; PHD2) inhibitors reported to be useful for the treatment of anemia, ischemia, cardiovascular disorders, inflammatory disorders, irritable bowel syndrome, chronic kidney disease, Parkinson’s disease and Alzheimer’s disease, among others. Read More
Iguana Merger Sub Inc. has described poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, but has limited treatment options. Bile acids, gut microbiota, nuclear receptors, lipid metabolism and fatty acid metabolism are believed to play a role in MASLD treatment and prevention. Read More
